SAN FRANCISCO, April 27, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that...
Hence then, the article about ibrx shareholder update immunitybio ibrx sued after fda flags misleading cancer claims shares plunge 21 2b market cap lost hagens berman was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman )
Also on site :
- 1982 No. 1 Hit, Written by Iconic Rock Band From California, Ranked Among ‘Greatest Soft Rock Songs’ of All Time
- Walmart’s Towering 73-Inch Bookcase Has Ample Storage for Enormous Book Collections, Now Nearly 40% Off
- Aimee Teegarden Returns to Hallmark Opposite ‘When Calls the Heart’ Star Chris McNally—See Our Exclusive Sneak Peek